Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease.

Authors

null

Saya Jacob

UCSF Hem/Onc Fellowship, San Francisco, CA

Saya Jacob , Adil Daud

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT05695898

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS9595)

DOI

10.1200/JCO.2023.41.16_suppl.TPS9595

Abstract #

TPS9595

Poster Bd #

356b

Abstract Disclosures

Similar Posters